{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T06:40:04Z","timestamp":1713940804944},"reference-count":20,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T00:00:00Z","timestamp":1343779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Pharmaceutics"],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1016\/j.ijpharm.2012.04.073","type":"journal-article","created":{"date-parts":[[2012,5,5]],"date-time":"2012-05-05T05:31:00Z","timestamp":1336195860000},"page":"57-62","source":"Crossref","is-referenced-by-count":14,"title":["Modulation of gastric pH by a buffered soluble effervescent formulation: A possible means of improving gastric tolerability of alendronate"],"prefix":"10.1016","volume":"432","author":[{"given":"L.A.","family":"Hodges","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.M.","family":"Connolly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Winter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.N.E.","family":"Stevens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Hayward","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.G.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijpharm.2012.04.073_bib0005","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1055\/s-2005-870129","article-title":"Pill-induced esophageal injury: endoscopic features and clinical outcomes","volume":"37","author":"Abid","year":"2005","journal-title":"Endoscopy"},{"key":"10.1016\/j.ijpharm.2012.04.073_bib0010","first-page":"1152","article-title":"Alendronate-associated esophageal injury: pathologic and endoscopic features","volume":"12","author":"Abraham","year":"1999","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.ijpharm.2012.04.073_bib0015","first-page":"347","article-title":"Tolerability of risedronate in postmenopausal women intolerant of alendronate","volume":"13","author":"Adachi","year":"2001","journal-title":"Aging"},{"key":"10.1016\/j.ijpharm.2012.04.073_bib0020","doi-asserted-by":"crossref","first-page":"564","DOI":"10.2460\/ajvr.1996.57.04.564","article-title":"Mechanisms of acid injury in porcine gastroesophageal mucosa","volume":"57","author":"Argenzio","year":"1996","journal-title":"Am. J. Vet. Res."},{"key":"10.1016\/j.ijpharm.2012.04.073_bib0025","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/j.1525-1497.2001.04189.x","article-title":"Comparison of the mineral content of tap water and bottled waters","volume":"16","author":"Azoulay","year":"2001","journal-title":"J. Gen. Intern. Med."},{"key":"10.1016\/j.ijpharm.2012.04.073_bib0030","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","article-title":"Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group","volume":"348","author":"Black","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.ijpharm.2012.04.073_bib0035","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1056\/NEJM199610033351412","article-title":"Pill esophagitis \u2013 the case of alendronate","volume":"335","author":"Castell","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijpharm.2012.04.073_bib0040","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0378-5173(01)00795-5","article-title":"The effect of pH change on the gastric emptying of liquids measured by electrical impedence tomography and pH-sensitive radiotelemetry capsule","volume":"227","author":"Chaw","year":"2001","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpharm.2012.04.073_bib0045","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1056\/NEJM199610033351403","article-title":"Esophagitis associated with the use of alendronate","volume":"335","author":"de Groen","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijpharm.2012.04.073_bib0050","doi-asserted-by":"crossref","first-page":"G576","DOI":"10.1152\/ajpgi.00014.2002","article-title":"Physiological and morphological effects of alendronate on rabbit esophageal epithelium","volume":"283","author":"Dobrucali","year":"2002","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.ijpharm.2012.04.073_bib0055","unstructured":"Fosamax\u00ae (alendronate sodium tablets and oral solution), Package Insert. Merck & Co., Inc., Whitehouse Station, NJ."},{"key":"10.1016\/j.ijpharm.2012.04.073_bib0060","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s00198-011-1796-6","article-title":"A reappraisal of generic bisphosphonates in osteoporosis","volume":"23","author":"Kanis","year":"2012","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.ijpharm.2012.04.073_bib0065","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1023\/A:1026155822121","article-title":"Comparison of the rates of disintegration, gastric emptying, and drug absorption following administration of a new and conventional paracetamol formulation, using \u03b3 scintigraphy","volume":"20","author":"Kelly","year":"2003","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ijpharm.2012.04.073_bib0070","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1056\/NEJM199511303332201","article-title":"Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group","volume":"333","author":"Liberman","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijpharm.2012.04.073_bib0075","unstructured":"Merck & Company New Drug Application (NDA) 21-575, available from the US Food and Drug Administration under the Freedom of Information Act, www.fda.gov."},{"key":"10.1016\/j.ijpharm.2012.04.073_bib0080","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1023\/A:1018894827961","article-title":"Esophageal irritation due to alendronate sodium tablets (possible mechanisms)","volume":"43","author":"Peter","year":"1998","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.ijpharm.2012.04.073_bib0085","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s00296-009-0940-5","article-title":"Differences in persistence safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysis","volume":"30","author":"Ringe","year":"2009","journal-title":"Rheumatol. Int."},{"key":"10.1016\/j.ijpharm.2012.04.073_bib0090","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s11657-011-0060-1","article-title":"Osteoporosis: burden health care provision and opportunities in the EU. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA)","volume":"6","author":"Str\u00f6m","year":"2011","journal-title":"Arch. Osteoporos."},{"key":"10.1016\/j.ijpharm.2012.04.073_bib0095","first-page":"1965","article-title":"14Day endoscopy study comparing risedronate and alendronate in postmenopausal women stratified by Helicobacter pylori status","volume":"29","author":"Thomson","year":"2002","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.ijpharm.2012.04.073_bib0100","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0002-9343(03)00362-0","article-title":"Early discontinuation of treatment for osteoporosis","volume":"115","author":"Tosteson","year":"2003","journal-title":"Am. J. Med."}],"container-title":["International Journal of Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S037851731200419X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S037851731200419X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T05:58:12Z","timestamp":1713938292000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S037851731200419X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8]]},"references-count":20,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["S037851731200419X"],"URL":"https:\/\/doi.org\/10.1016\/j.ijpharm.2012.04.073","relation":{},"ISSN":["0378-5173"],"issn-type":[{"value":"0378-5173","type":"print"}],"subject":[],"published":{"date-parts":[[2012,8]]}}}